Saab, C., Al-Saber, F. A., Haddad, J., Jallo, M. K., Steitieh, H., Bader, G., & Ibrahim, M. (2015). Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: Results from the EDGE study. Vasc Health Risk Manag.

Saab, Charles, Feryal A. Al-Saber, Jihad Haddad, Mahir Khalil Jallo, Habib Steitieh, Giovanni Bader, et Mohamed Ibrahim. "Effectiveness and Tolerability of Second-line Treatment With Vildagliptin Versus Other Oral Drugs for Type 2 Diabetes in a Real-world Setting in the Middle East: Results From the EDGE Study." Vasc Health Risk Manag 2015.

Saab, Charles, et al. "Effectiveness and Tolerability of Second-line Treatment With Vildagliptin Versus Other Oral Drugs for Type 2 Diabetes in a Real-world Setting in the Middle East: Results From the EDGE Study." Vasc Health Risk Manag 2015.